Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease

Immunologic Research

Volumn 35, Issue 3, 2006, Pages 233-248

  Batzloff, Michael R ^a   Pandey, Manisha ^a   Olive, Colleen ^a   Good, Michael F ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antimicrobials; Conjugation; Lipids; Peptide; Streptococcus; Vaccine

Indexed keywords

BACTERIAL PROTEIN; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA TOXOID; FREUND ADJUVANT; LIPOPEPTIDE; OUTER MEMBRANE PROTEIN; POLYMER; STREPTOCOCCUS M PROTEIN; STREPTOCOCCUS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONJUGATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

EID: 33845888537     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:35:3:233     Document Type: Review

References (77)

1. WHO: Global Polio Eradication Initiative : Strategic Plan 2004-2008. World Health Organization, Geneva, 2003.
2. Merrifield RB: Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85: 2149-2153.
3. Carpino LA, Han GY: The 9-fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 1972;37:3404-3409.
4. Fields GB, Nobel RL: Solid phase peptide synthesis utilizing 9- fluorenylmethoxycarbonyl amino acids. Intern J Pep Prot Res 1990;35:161-214.
5. Cherry DK, Woodwell DA: National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002;1-32.
6. Bisno AL: Acute pharyngitis. N Engl J Med 2001; 344:205-211.
7. Bisno AL, Rubin FA, Cleary PP, Dale JB: Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles - report of a National Institute of Allergy and Infectious Diseases Workshop. Clin Infect Dis 2005;41:1150-1156.
8. Komaroff AL, Pass TM, Aronson MD, et al: The prediction of streptococcal pharyngitis in adults. J Gen Intern Med 1986;1:1-7.
9. Massell BF: Rheumatic fever and streptococal infection. Harvard University Press, Boston, 1997.
10. Cunningham MW: Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.
11. Steer AC, Carapetis JR, Nolan TM, Shann F: Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002;38:229-234.
12. Carapetis JR, Wolff DR, Currie BJ: Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 1996;164: 146-149.
13. World Health Organization: World Health Report. Office of Publications, World Health Organization, Geneva, 2000, pp. 164-169.
14. Carapetis J: A review of WHO activities in, the burden of, and the evidence for strategies to control group A streptococcal diseases: part 3 - the current evidence for the burden of group A streptococcal diseases. University of Melbourne, Melbourne, 2004, pp. 1-49.
15. Carapetis JR, Steer AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-694.
16. Thomson D, Thomson R: The role of the Streptococci in scarlet fever. Annals of the Pickett-Thomson Research Laboratory 1930;4:244-252.
17. Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL: Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979;150: 862-877.
18. Fox EN, Wittner MK, Dorfman A: Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med 1966;124:1135-1151.
19. Massell BF, Michael JG, Amezcua J, Siner M: Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968;16:509-518.
20. Fox EN, Pachman LM, Wittner MK, Dorfman A: Primary immunization of infants and children with group A streptococcal M protein. J Infect Dis 1969;120: 598-604.
21. Lyampert IM, Danilova TA, Borodyuk NA, Beletskaya LV: Mechanism of formation of antibodies to heart tissue in immunization with group A streptococci. Folia Biol (Praha) 1966;12:108-115.
22. Beachey EH, Stollerman GH: The common antigen(s) of streptococcal M protein vaccines causing hyperimmune reactions in man. Trans Assoc Am Physicians 1972; 85:212-221.
23. Massell BF, Honikman LH, Amezcua J: Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969;207:1115-1119.
24. Fox EN: M proteins of group A streptococci. Bacteriol Rev 1974;38:57-86.
25. Park HS, Cleary PP: Active and passive intranasal immunizations with streptococcal surface protein c5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005;73:7878-7886.
26. McMillan DJ, Batzloff MR, Browning CL, et al: Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004;22: 2783-2790.
27. Zabriskie JB, Poon-King T, Blake MS, Michon F, Yoshinaga M: Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol 1997;418:917-919.
28. Fischetti VA, Jones KF, Hollingshead SK, Scott JR: Structure, function, and genetics of streptococcal M protein. Rev Infect Dis 1988;10(Suppl 2):S356-359.
29. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB: Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002;70:2171-2177.
30. Kotloff KL, Corretti M, Palmer K, et al: Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004;292:709-715.
31. Bessen D, Fischetti VA: Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988;56:2666-2672.
32. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B: Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005;12:833-836.
33. McNeil SA, Halperin SA, Langley JM, et al: Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-1122.
34. Bessen D, Fischetti VA: Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 1988;167:1945-1950.
35. Brandtzaeg P: Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003;293:3-15.
36. Bronze MS, Courtney HS, Dale JB: Epitopes of groupa streptococcal M-protein that evoke cross-protective local immune-responses. J Immunol 1992;148:888-893.
37. Pruksakorn S, Currie B, Brandt E, et al: Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 1994;344:639-642.
38. Pruksakorn S, Galbraith A, Houghten RA, Good MF: Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 1992;149:2729-2735.
39. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF: Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997;9:1723-1733.
40. Brandt ER, Hayman WA, Currie B, et al: Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996;89:331-337.
41. Batzloff M, Yan H, Davies M, Hartas J, Good M: Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004;119(Suppl):104-107.
42. Batzloff MR, Hayman WA, Davies MR, et al: Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003;187:1598-1608.
43. Batzloff MR, Yan H, Davies MR, et al: Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 2005;192:1450-1455.
44. Brandt ER, Hayman WA, Currie B, et al: Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol 1999;11:569-576.
45. D'Alessandri R, Plotkin G, Kluge RM, et al: Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978;138:712-718.
46. Brandt ER, Teh T, Relf WA, Hobb RI, Good MF: Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000;68:6587-6594.
47. Olive C, Clair T, Yarwood P, Good MF: Protection of mice from group A streptococcal infection by intranasal immunization with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002;20:2816-2825.
48. Bran5dt ER, Sriprakash KS, Hobb RI, et al: New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 2000;6:455-459.
49. Jackson DC, O'Brien-Simpson N, Ede NJ, Brown LE: Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 1997; 15:1697-1705.
50. Hantke K, Braun V: Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein- lipoprotein of the Escherichia coli outer membrane. Eur J Biochem 1973;34:284-296.
51. Luke CJ, Huebner RC, Kasmiersky V, Barbour AG: Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Vaccine 1997;15:739-746.
52. Keller D, Koster FT, Marks DH, Hosbach P, Erdile LF, Mays JP: Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994; 271:1764-1768.
53. Melchers F, Braun V, Galanos C: The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. Exp Med 1975;142:473-482.
54. Norgard MV, Arndt LL, Akins DR, Curetty LL, Harrich DA, Radolf JD: Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-[kappa]B. Infect Immun 1996;64:3845-3852.
55. Kreutz M, Ackermann U, Hauschildt S, et al: A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and staphyloccocus aureus in human monocytes. Immunology 1997;92:396-401.
56. Wiesmuller KH, Bessler W, Jung G: Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe Seyler Physiol Chem 1983;364:593-606.
57. Hoffmann P, Heinle S, Schade UF, et al: Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology 1988;177:158-170.
58. Seifert R, Schultz G, Richter-Freund M, et al: Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem J 1990;267:795-802.
59. Berg M, Offermanns S, Seifert R, Schultz G: Synthetic lipopeptide Pam3CysSer(Lys)4 is an effective activator of human platelets. Am J Physiol 1994;266:C1684-C1691.
60. Wiesmuller K-H, Jung G, Hess G: Novel low-molecularweight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 1989;7:29-33.
61. Re F, Strominger J-L: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001;276:37692-37699.
62. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
63. Jackson DC, Lau YF, Le T, et al: A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440-15445.
64. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC: Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002;169:4905-4912.
65. Tam JP: Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988;85:5409-5413.
66. Olive C, Batzloff MR, Toth I: Lipid core peptide technology and group A streptococcal vaccine delivery. Expert Rev Vaccines 2004;3:43-58.
67. McGeary RP, Olive C, Toth I: Lipid and carbohydrate based adjuvant/carriers in immunology. J Pept Sci 2003;9:405-418.
68. Olive C, Toth I, Jackson D: Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 2001;1:429-438.
69. Wong A, Toth I: Lipid, sugar and liposaccharide based delivery systems. Curr Med Chem 2001;8:1123-1136.
70. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF: Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002;80:178-187.
71. Olive C, Batzloff MR, Horvath A, et al: A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002;70: 2734-2738.
72. Olive C, Batzloff M, Horvath A, et al: Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003;71:2373-2383.
73. Olive C, Hsien K, Horvath A, et al: Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005;23:2298-2303.
74. Lowell G, Burt DS, White GL, Fries LF: Proteosome™ technology for vaccines and adjuvants; in: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (eds). New Generation Vaccines, 3rd ed. Marcel Dekker, New York, 2004; pp. 271-282.
75. Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM: Cutting edge: immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168:1533-1537.
76. Mannam P, Jones KF, Geller BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004;72:3444-3450.
77. Ferretti JJ, McShan WM, Ajdic D, et al: Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci USA 2001;98:4658-4663.